Published in Aging and Elder Health Week, August 21st, 2005
AlzheimAlert remains approved for sale in the U.S. as a laboratory testing service through the company's clinical reference laboratory in New Jersey. Nasdaq halted NYMX trading during the panel meeting in order to maintain an orderly market.
"We are very pleased to have had the opportunity to present the results of the blinded 9-center trial which showed that 89.5% of clinical cases of probable AD [Alzheimer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.